Ikarian Capital, LLC Insmed Inc Transaction History

Ikarian Capital, LLC

$606 Million
Q4 2024

A detailed history of Ikarian Capital, LLC transactions in Insmed Inc stock. As of the latest transaction made, Ikarian Capital, LLC holds 150,000 shares of INSM stock, worth $12.2 Million. This represents 1.71% of its overall portfolio holdings.

Number of Shares

150,000

Previous 154,835 3.12%

Holding current value

$12.2 Million

Previous $11.3 Million 8.37%

% of portfolio

1.71%

Previous 1.97%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$66.29 - $76.63 $2.32 Million - $2.68 Million	-35,035 Reduced 22.63%	119,800 $8.27 Million
Q3 2024 Nov 14, 2024	BUY	$62.0 - $79.01 $6.63 Million - $8.45 Million	107,000 Added 223.69%	154,835 $11.3 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $77,000 - $243,984	-3,500 Reduced 6.82%	47,835 $3.2 Million
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $1.32 Million - $1.54 Million	51,335 New	51,335 $1.39 Million
Q3 2023 Nov 14, 2023	SELL	$19.86 - $26.93 $6.56 Million - $8.89 Million	-330,100 Reduced 68.06%	154,900 $3.91 Million
Q1 2023 May 15, 2023	BUY	$16.26 - $21.73 $7.89 Million - $10.5 Million	485,000 New	485,000 $8.27 Million
Q2 2022 Aug 12, 2022	BUY	$17.07 - $25.71 $2.13 Million - $3.21 Million	125,000 New	125,000 $2.47 Million
Q3 2020 Nov 16, 2020	SELL	$26.0 - $34.5 $75,894 - $100,705	-2,919 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$14.11 - $29.42 $2.4 Million - $5 Million	-170,000 Reduced 98.31%	2,919 $80,000
Q1 2020 May 15, 2020	BUY	$13.63 - $33.98 $2.36 Million - $5.88 Million	172,919 New	172,919 $2.77 Million

Others Institutions Holding INSM

# of Institutions

497

Shares Held

189M

Call Options Held

3.21M

Put Options Held

2.72M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $11B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Account

Ikarian Capital, LLC Insmed Inc Transaction History